TOVX Key Statistics, Chart & Performance
The current stock price of TOVX is 0.2059 USD. In the past month the price decreased by -36.65%. In the past year, price decreased by -83.79%.
TOVX Latest News, Press Relases and Analysis
TOVX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.55B | ||
| AMGN | AMGEN INC | 15.47 | 182.20B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 153.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.95 | 109.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 911.63 | 61.42B | ||
| INSM | INSMED INC | N/A | 44.06B | ||
| NTRA | NATERA INC | N/A | 32.66B | ||
| BIIB | BIOGEN INC | 10.76 | 26.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.97 | 20.42B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About TOVX
Company Profile
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. The company is headquartered in Rockville, Maryland and currently employs 22 full-time employees. The firm is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Company Info
THERIVA BIOLOGICS INC
9605 Medical Center Drive, Suite 270
Rockville MARYLAND US
Employees: 21
Phone: 17343327800
THERIVA BIOLOGICS INC / TOVX FAQ
What does THERIVA BIOLOGICS INC do?
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. The company is headquartered in Rockville, Maryland and currently employs 22 full-time employees. The firm is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
What is the stock price of THERIVA BIOLOGICS INC today?
The current stock price of TOVX is 0.2059 USD. The price decreased by -5.94% in the last trading session.
Does THERIVA BIOLOGICS INC pay dividends?
TOVX does not pay a dividend.
What is the ChartMill technical and fundamental rating of TOVX stock?
TOVX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does THERIVA BIOLOGICS INC belong to?
THERIVA BIOLOGICS INC (TOVX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the upcoming earnings date for THERIVA BIOLOGICS INC?
THERIVA BIOLOGICS INC (TOVX) will report earnings on 2026-03-04, after the market close.
TOVX Technical Analysis
TOVX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TOVX. TOVX may be in some trouble as it scores bad on both profitability and health.
TOVX Financial Highlights
Over the last trailing twelve months TOVX reported a non-GAAP Earnings per Share(EPS) of -5.87. The EPS increased by 7.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.49% | ||
| ROE | -278.22% | ||
| Debt/Equity | 0.15 |
TOVX Forecast & Estimates
8 analysts have analysed TOVX and the average price target is 7.14 USD. This implies a price increase of 3367.7% is expected in the next year compared to the current price of 0.2059.